Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 11, 2023; 100 (15) Disputes & Debates: Editors' Choice

Editors' Note: Effect of Cholinesterase Inhibitors on Mortality in Patients With Dementia: A Systematic Review of Randomized and Nonrandomized Trials

James E Siegler, View ORCID ProfileSteven Galetta
First published April 10, 2023, DOI: https://doi.org/10.1212/WNL.0000000000207225
James E Siegler
M.D
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Galetta
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven Galetta
Full PDF
Citation
Editors' Note: Effect of Cholinesterase Inhibitors on Mortality in Patients With Dementia: A Systematic Review of Randomized and Nonrandomized Trials
James E Siegler, Steven Galetta
Neurology Apr 2023, 100 (15) 736; DOI: 10.1212/WNL.0000000000207225

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
19

Share

  • Article
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Cholinesterase inhibitors such as galantamine and donepezil are among the few medications available that may slow the signs of dementia. However, their effects are modest, and the side effect profile may preclude their use in many patients. If additional benefit from these medications is found, it may encourage providers to prescribe these inexpensive and widely available agents. To explore other potential benefits of cholinesterase inhibitors, Dr. Truong and colleagues meta-analyzed the available clinical trial and longitudinal high-quality observational cohort data reporting mortality rates associated with cholinesterase inhibitor use vs placebo among patients with dementia. Across 24 included studies (n = 12 randomized clinical trials), there was a strong and significant reduction in the risk of death with cholinesterase inhibitor use among all-comers with dementia (adjusted RR 0.77, 95% CI 0.70–0.84). The estimated number needed to treat to avoid 1 death was 29. Similar effect estimates were confirmed across subgroup and in sensitivity analyses. Dr. Watt et al. commented on the technical aspects of the systematic review and meta-analysis, suggesting that the authors may have excluded other eligible trials and imprecisely assessed study bias. The authors note that many trials were excluded because of the short duration of the follow-up, which could have failed to capture any mortality difference (and would only be detectable after a considerable follow-up period). Additional clarifications were made regarding the analytic approach (protocol deviations) and the justification of post hoc comparisons, which have important clinical implications. Such secondary findings may shed light on treatment opportunities for specific populations of patients with dementia. This exchange underscores the value placed on a prespecified study methodology while also permitting an appropriate level of exploratory analyses that may be clinically relevant.

Cholinesterase inhibitors such as galantamine and donepezil are among the few medications available that may slow the signs of dementia. However, their effects are modest, and the side effect profile may preclude their use in many patients. If additional benefit from these medications is found, it may encourage providers to prescribe these inexpensive and widely available agents. To explore other potential benefits of cholinesterase inhibitors, Dr. Truong and colleagues meta-analyzed the available clinical trial and longitudinal high-quality observational cohort data reporting mortality rates associated with cholinesterase inhibitor use vs placebo among patients with dementia. Across 24 included studies (n = 12 randomized clinical trials), there was a strong and significant reduction in the risk of death with cholinesterase inhibitor use among all-comers with dementia (adjusted RR 0.77, 95% CI 0.70–0.84). The estimated number needed to treat to avoid 1 death was 29. Similar effect estimates were confirmed across subgroup and in sensitivity analyses. Dr. Watt et al. commented on the technical aspects of the systematic review and meta-analysis, suggesting that the authors may have excluded other eligible trials and imprecisely assessed study bias. The authors note that many trials were excluded because of the short duration of the follow-up, which could have failed to capture any mortality difference (and would only be detectable after a considerable follow-up period). Additional clarifications were made regarding the analytic approach (protocol deviations) and the justification of post hoc comparisons, which have important clinical implications. Such secondary findings may shed light on treatment opportunities for specific populations of patients with dementia. This exchange underscores the value placed on a prespecified study methodology while also permitting an appropriate level of exploratory analyses that may be clinically relevant.

Footnotes

  • Author disclosures are available upon request (journal{at}neurology.org).

  • See letter

  • See response

  • © 2023 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Footnotes
  • Info & Disclosures
Advertisement

Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease–Related Dementias

Dr. Sevil Yaşar and Dr. Behnam Sabayan

► Watch

Related Articles

  • Reader Response: Effect of Cholinesterase Inhibitors on Mortality in Patients With Dementia: A Systematic Review of Randomized and Nonrandomized Trials
  • Author Response: Effect of Cholinesterase Inhibitors on Mortality in Patients With Dementia: A Systematic Review of Randomized and Nonrandomized Trials

Alert Me

  • Alert me when eletters are published
Neurology: 101 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise